SCHEMBL3594420

SCHEMBL3594420

COc1ccc(-n2nccc2-c2ccc(OC)c(Br)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.51
MAPT P10636 4/20 0.49
MAPK8 P45983 1/20 0.43
MAPK9 P45984 1/20 0.43
MAPK10 P53779 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
DGAT1 O75907 1/20 0.41
PTGS2 P35354 4/20 0.41
PTGS1 P23219 3/20 0.41
NPBWR1 P48145 1/20 0.40
LMNA P02545 1/20 0.40
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
MAOB P27338 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
NPC1 O15118 1/20 0.39
ALOX12 P18054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3609867 0.88 NR3C2 (0.57) NR3C2MAPTMAPK8MAPK9MAPK10
SCHEMBL3609486 0.84 NR3C2 (0.51) NR3C2MAPTMAPK8MAPK9MAPK10
SCHEMBL27932702 0.82 NR3C2 (0.51) NR3C2MAPTMAPK9MAPK10NPSR1
SCHEMBL3611670 0.80 NR3C2 (0.47) NR3C2MAPTMAPK8MAPK9MAPK10
SCHEMBL15556699 0.80 NR3C2 (0.54) NR3C2MAPTMAPK8MAPK9MAPK10
SCHEMBL3606259 0.79 NR3C2 (0.48) NR3C2MAPTMAPK8MAPK9MAPK10
SCHEMBL4809023 0.78 MAPT (0.57) NR3C2MAPTMAPK8MAPK9MAPK10
SCHEMBL17086615 0.77 MAPT (0.52) NR3C2MAPTNPSR1DGAT1PTGS2
SCHEMBL16911718 0.77 BRD4 (0.50) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL28300954 0.76 SMN1; SMN2 (0.50) NR3C2MAPTMAPK8MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060154960-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2006-07-13 US claimed
US-7723348-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2010-05-25 US disclosed
US-7723348-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2010-05-25 US disclosed
US-7723348-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2010-05-25 US disclosed
US-7432266-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2008-10-07 US disclosed
US-7432266-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2008-10-07 US disclosed
US-7432266-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2008-10-07 US disclosed
US-20080207660-A1 PHOSPHODIESTERASE 4 INHIBITORS HOPPER ALLEN 2008-08-28 US disclosed
US-20080207660-A1 PHOSPHODIESTERASE 4 INHIBITORS HOPPER ALLEN 2008-08-28 US disclosed
US-20080207660-A1 PHOSPHODIESTERASE 4 INHIBITORS HOPPER ALLEN 2008-08-28 US disclosed
US-20070254913-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-01 US disclosed
US-20060154960-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2006-07-13 US disclosed
WO-2006044528-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254913-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 NR3C2 646/4885MAPT 3815/4885MAPK8 2493/4885
US-20080207660-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE12 NR3C2 646/4885MAPT 3815/4885MAPK8 2493/4885
US-20060154960-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 NR3C2 646/4885MAPT 3815/4885MAPK8 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.